Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07439666 · ClinicalTrials.gov registry record · NA
NEUROCUPLE™ as an Opioid Alternative Following Total Knee Arthroplasty
A NA study, sponsored by Jacques E. Chelly.
- Not yet
- Registry status
- NA
- Development phase
- 274
- Enrollment target
NCT07439666: Clinical Trial NA study, sponsored by Jacques E. Chelly.
NCT07439666 is a NA study that has not yet begun recruiting, run by Jacques E. Chelly. The registered enrollment target is 274 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07439666, a NA study, has not yet begun recruiting, sponsored by Jacques E. Chelly.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 274 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if the NEUROCUPLE device can reduce pain and opioid use after primary unilateral total knee arthroplasty (TKA) in adults. The main questions it aims to answer are: * Does the NEUROCUPLE device reduce postoperative pain at rest during the first 24 hours after TKA? * Does the NEUROCUPLE device reduce opioid consumption during the first 24 hours after TKA? Researchers will compare the NEUROCUPLE device to a placebo device (identical in appearance but inactive) to see if the device reduces pain and opioid use after surgery. Participants will: * Apply the NEUROCUPLE device or placebo device for 7 days following surgery * Have their pain and opioid use monitored through clinical records and patient reporting * Report pain at rest and during movement on postoperative Days 2 and 7 * Be assessed for nausea, vomiting, device-related side effects, length of hospital stay, and overall satisfaction
Primary Outcome
Total opioid consumption, expressed in milligrams of morphine equivalents (MME), during the first 24 hours following surgery. Opioid use will be calculated using all available data sources, including in-hospital medication administration records and, when applicable, the state Prescription Drug Monitoring Program (PDMP). MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved pos
Interventions
- DEVICE NEUROCUPLE™ Patch
- DEVICE Sham patch
- OTHER Enhanced Recovery After Surgery (ERAS) Standard of Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2026-12 |
| Est. Completion | 2027-11 |
| Phase | NA |
What is known before NCT07439666 opens enrollment
NCT07439666 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 3 interventions - of which NEUROCUPLE™ Patch is the first listed.
NCT07439666 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07439666 about?
NCT07439666 is a clinical study titled "NEUROCUPLE™ as an Opioid Alternative Following Total Knee Arthroplasty". The goal of this clinical trial is to learn if the NEUROCUPLE device can reduce pain and opioid use after primary unilateral total knee arthroplasty (TKA) in adults. The main questions it aims to answer are: * Does the NEUROCUPLE device reduce postoperative pain at rest during the first 24 hours a...
What is the current status of trial NCT07439666?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 274 participants. The study started on 2026-12. Estimated completion is 2027-11.
What interventions are being tested in trial NCT07439666?
The interventions under investigation include: NEUROCUPLE™ Patch (DEVICE), Sham patch (DEVICE), Enhanced Recovery After Surgery (ERAS) Standard of Care (OTHER).
Who is sponsoring clinical trial NCT07439666?
This trial is sponsored by Jacques E. Chelly, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07439666's enrollment target sits among peer trials
274 385th of 2000 higher than 1,615 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
- NCT05952583 · 274 participants
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia